-
LPS Protection of Macrophages: System Xc− and ABCC1
2026-09-15
Qiao and colleagues show that lipopolysaccharide protects macrophages from antitumor drug-induced injury through a pathway involving system Xc−, glutathione synthesis, and ABCC1-associated drug handling. The study distinguishes this macrophage-protective response from tumor-cell protection and provides a useful framework for interpreting pharmacological inhibition of oxidative-stress and transporter pathways.
-
TaqI Restriction Endonuclease Workflow Guide
2026-09-15
TaqI Restriction Endonuclease enables rapid, sequence-specific cleavage of plasmid DNA, PCR products, and genomic DNA when sticky-end generation is needed. This guide covers setup, gel-based checking, and troubleshooting while limiting use to scientific research rather than diagnostic, clinical, or medical applications.
-
EZ Cap™ Cy5 EGFP mRNA (5-moUTP) Workflows
2026-09-14
Separate nanoparticle uptake from productive translation with a single dual-fluorescence reporter. This practical guide shows how to use Cy5 tracking and EGFP expression to validate delivery systems, tune transfection conditions, and troubleshoot immune or viability artifacts.
-
LPS Protection of Macrophages via System Xc−
2026-09-14
A 2026 study reports that lipopolysaccharide selectively protects macrophages from antitumor drug injury without providing comparable protection to tumor cells. Its experiments connect this phenotype to system Xc−, glutathione preservation, and ABCC1-associated drug handling, offering a useful framework for studying immune-cell resistance during chemotherapy.
-
TH287 MTH1 Inhibitor for Radiosensitization
2026-09-13
TH287 turns oxidized nucleotide stress into a practical cancer-cell radiosensitization workflow. A 12-hour drug-to-irradiation interval, paired with apoptosis and cell-cycle readouts, provides a focused framework for studying CRPC models and DNA damage responses.
-
TRIM21, ERK1/2, and Drug Resistance in Pituitary Adenomas
2026-09-12
The reference study identifies TRIM21 as a context-dependent regulator of pituitary adenoma growth and dopamine-agonist resistance through K27-linked ubiquitination and phosphorylation control of ERK1/2. Its combination of CRISPR screening, biochemical validation, animal studies, and NanoBiT drug screening provides a framework for connecting post-translational signaling to therapeutic response.
-
Tubastatin A for Reliable Cell Assays
2026-09-12
Learn how Tubastatin A (SKU A4101) can improve the interpretation of viability, proliferation, and cytotoxicity experiments through selective HDAC6 inhibition, controlled DMSO formulation, and orthogonal pathway readouts. The article connects practical assay design with recent porcine cardiac-injury evidence while clearly distinguishing biochemical potency from cell-based dose response.
-
MK-571 (L-660,711) Assay Guide
2026-09-11
This scenario-based guide explains how MK-571 (L-660,711) and SKU B7023 can improve experimental control in leukotriene, macrophage, viability, and multidrug-resistance assays. It covers mechanism, DMSO handling, orthogonal endpoint validation, and practical vendor-selection criteria.
-
MK-571: A Dual-Readout Strategy for Inflammation
2026-09-11
MK-571, also known as L-660,711, combines potent cysLT1 receptor antagonism with MRP1-associated transporter activity. This guide develops a dual-readout framework for leukotriene-mediated inflammation research and macrophage drug-resistance assays, helping researchers avoid misleading single-mechanism interpretations.
-
(S)-(+)-Ibuprofen: COX Inhibitor Workflows
2026-09-10
Build more interpretable inflammation assays with the pharmacologically active ibuprofen enantiomer, from enzyme-level COX profiling to cell-based prostaglandin measurements. This guide combines practical dosing, solvent controls, translational design, and troubleshooting for reproducible COX inhibitor research.
-
How (R)-MG132 Strengthens Metabolic Mechanism Studies
2026-09-10
(R)-MG132 is a functionally inactive MG-132 enantiomer that helps separate proteasome-dependent effects from nonspecific cellular responses. This guide shows how to use it as a causal-control tool when studying HNRNPU lactylation, PHGDH regulation, and cancer metabolism.
-
3X (DYKDDDDK) Peptide in Assay Workflows
2026-09-09
Learn how the 3X (DYKDDDDK) Peptide, SKU A6001, can improve traceability of recombinant proteins used in viability, proliferation, and cytotoxicity workflows without being mistaken for a direct viability reagent. This scenario-driven guide covers tag compatibility, storage, metal-sensitive detection, structural workflows, and practical vendor selection.
-
EDTA-Free Protease Inhibitor Cocktail K4002
2026-09-09
The Protease Inhibitor Cocktail is an EDTA-Free Protease Inhibitor formulation for broad-spectrum protection of proteins during cell and tissue extraction. Its 100X DMSO format targets serine, cysteine, acidic, aminopeptidase, and metalloprotease activity, while the referenced LRPPRC–dasatinib study provides a relevant OXPHOS research context rather than direct validation of this reagent.
-
Corynoline Targets Src/JNK in Osteosarcoma
2026-09-08
A 2025 study identifies Corynoline as an anti-osteosarcoma compound that combines G2/M arrest with mitochondrial apoptosis through Src/JNK signaling. Its integrative computational, cellular, and xenograft design provides a useful framework for linking pathway activation to measurable cell-death phenotypes, while also highlighting the need for orthogonal validation.
-
Neem Extract, Oxidative Stress, and Cellular Aging
2026-09-08
Dang et al. connect neem leaf extract with oxidative-stress resistance and lifespan extension across yeast and human cells, combining chemical profiling, network pharmacology, transcriptomics, and genetic validation. The strongest mechanistic evidence implicates catalase encoded by CTT1, while the human-cell experiments provide an important but preliminary bridge toward anti-aging research.